This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Nov 1;172(9):1228-9; author reply 1229.

doi: 10.1164/ajrccm.172.9.951.

Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF

Joseph Levitt, Michael K Gould

PMID: 16249322
DOI: 10.1164/ajrccm.172.9.951

Comment

Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF

Joseph Levitt et al. Am J Respir Crit Care Med. 2005.

. 2005 Nov 1;172(9):1228-9; author reply 1229.

doi: 10.1164/ajrccm.172.9.951.

Authors

Joseph Levitt, Michael K Gould

PMID: 16249322
DOI: 10.1164/ajrccm.172.9.951

No abstract available

PubMed Disclaimer

Comment on

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S. Azuma A, et al. Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7. doi: 10.1164/rccm.200404-571OC. Epub 2005 Jan 21. Am J Respir Crit Care Med. 2005. PMID: 15665326 Clinical Trial.

Similar articles

The questionable efficacy of pirfenidone in IPF.
Mathai SC, Polito AJ. Mathai SC, et al. Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228. doi: 10.1164/ajrccm.172.9.950. Am J Respir Crit Care Med. 2005. PMID: 16249323 No abstract available.
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S. Azuma A, et al. Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7. doi: 10.1164/rccm.200404-571OC. Epub 2005 Jan 21. Am J Respir Crit Care Med. 2005. PMID: 15665326 Clinical Trial.
[Idiopathic pulmonary fibrosis -- progress in sight].
Kaarteenaho R, Hodgson U, Myllärniemi M. Kaarteenaho R, et al. Duodecim. 2011;127(24):2639-45. Duodecim. 2011. PMID: 22320106 Review. Finnish.
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Poletti V, Ravaglia C, Tomassetti S. Poletti V, et al. Expert Rev Respir Med. 2014 Oct;8(5):539-45. doi: 10.1586/17476348.2014.915750. Epub 2014 Aug 12. Expert Rev Respir Med. 2014. PMID: 25113033 Review.
Is idiopathic pulmonary fibrosis now treatable?
du Bois RM. du Bois RM. Am J Respir Crit Care Med. 2005 May 1;171(9):939-40. doi: 10.1164/rccm.2502001. Am J Respir Crit Care Med. 2005. PMID: 15849328 No abstract available.

See all similar articles

Cited by

Targeted therapy for systemic sclerosis: how close are we?
Ramos-Casals M, Fonollosa-Pla V, Brito-Zerón P, Sisó-Almirall A. Ramos-Casals M, et al. Nat Rev Rheumatol. 2010 May;6(5):269-78. doi: 10.1038/nrrheum.2010.48. Epub 2010 Apr 13. Nat Rev Rheumatol. 2010. PMID: 20386562 Review.
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.
Hirano A, Kanehiro A, Ono K, Ito W, Yoshida A, Okada C, Nakashima H, Tanimoto Y, Kataoka M, Gelfand EW, Tanimoto M. Hirano A, et al. Am J Respir Cell Mol Biol. 2006 Sep;35(3):366-77. doi: 10.1165/rcmb.2005-0452OC. Epub 2006 May 4. Am J Respir Cell Mol Biol. 2006. PMID: 16675785 Free PMC article.
Pirfenidone treatment of idiopathic pulmonary fibrosis.
Gan Y, Herzog EL, Gomer RH. Gan Y, et al. Ther Clin Risk Manag. 2011 Feb 8;7:39-47. doi: 10.2147/TCRM.S12209. Ther Clin Risk Manag. 2011. PMID: 21339942 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information